Abbott’s ABT diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving ABT Shares Within ...

In 2024, Abbott obtained FDA approvals for two new over-the-counter CGMs called Lingo and Libre Rio, which are based on Libre’s technology. The technology is now used by more than 6 million ...

Of late, the company has been gaining momentum, leveraging consistent upgrades of FreeStyle Libre. In 2024, Abbott obtained FDA approvals for two new over-the-counter CGMs called Lingo and Libre Rio, ...

The Libre 2 and 3 labels now say that patients can safely undergo a 1.5T or 3T field strength MRI exam while wearing the sensor, under specific listed conditions. Scanning between the pelvis and ...

In June 2024, the FDA approved Abbott's two new over-the-counter continuous glucose monitoring (CGM) systems: Lingo and Libre Rio. Abbott has been expanding their product offerings in the CGM market.

Earlier, in June 2024, the U.S. FDA cleared Abbott’s – Libre Rio and Lingo – new over-the-counter glucose monitoring devices. This should also aid the overall diabetes portfolio sales.

Lingo is based on Abbott’s FreeStyle Libre continuous glucose monitoring technology. Abbott’s consumer biowearable, Lingo, is available for consumers 18 years and older not on insulin.

In January, Abbott's FreeStyle Libre 2 Plus sensor was cleared by the U.S. Food & Drug Administration to work with the Tandem t:slim X2 insulin pump, creating a hybrid closed-loop insulin delivery ...

A small number of sensors that read blood sugar levels continuously may give incorrect info. Here's how to check your FreeStyle Libre 3 for a replacement.

The FreeStyle Libre 3’s reader and app were unaffected, as were other products in the FreeStyle Libre line. A company spokesperson said Abbott estimates the issue will affect less than 1% of ...

It could be a multi-billion-dollar product for Abbott, Ford estimated, adding it was still in its early days. Lingo and Libre Rio, another of Abbott's devices, received clearance from the U.S ...

Libre Rio Libre Rio will be Abbott’s first over-the-counter CGM system for people with diabetes in the U.S.